

Galectin-9 triggers neutrophil-mediated anticancer immunity

Natasha Ustyanovska Avtenyuk ^{1,†}, Ghizlane Choukrani ^{1,†}, Emanuele Ammatuna ¹, Toshiro Niki ², Ewa Cendrowicz ¹, Harm Jan Lourens ¹, Gerwin Huls ¹, Valerie R. Wiersma ^{1,*} and Edwin Bremer ^{1,*}

¹ Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, 9713 GZ Groningen, The Netherlands. n.ustyanovska.avtenyuk@umcg.nl (N.U.A.); g.choukrani@umcg.nl (G.C.); e.ammatus@umcg.nl (E.A.); niki.toshiro@kagawa-u.ac.jp (T.N); e.krol@umcg.nl (E.C.); h.j.lourens@umcg.nl (H.J.L.); g.huls@umcg.nl (G.H.)

² Department of Immunology, Kagawa University, Takamatsu, Kagawa 760-0016, Japan

* Correspondence: e.bremer@umcg.nl (E.B); v.wiersma@umcg.nl (V.R.W.).

† These authors contributed equally.




Figure S1. Gal-9-mediated trogocytosis can largely be attributed to neutrophil activation. (A) Blockade of Gal-9 mediated expression of PSCD47 on FaDu with α -lactose. (B) Gal-9 pre-treated DLD-1 potentiates antibody-dependent cellular phagocytosis (ADCP) with CTX. (C-E) Expression of the activation markers CD11b and CD62L on neutrophils after treatment with Gal-9/fMLP/LPS. (F) TIM-3 expression on neutrophils. (G-L) Expression of different granules markers on Gal-9 treated neutrophils.




Figure S2: Gal-9 mediated the cytotoxic elimination of different carcinoma cell lines by leukocytes. (A) ICAM-1 expression on FaDu as determined by flow cytometry in a mixed culture with neutrophils and Gal-9. **(B-C)** Viability of FaDu in a mix culture with Gal-9 and neutrophils. **(C)** Viability of FaDu Flip-GFP Mcherry in a mix culture with Gal-9 and neutrophils.